Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: The experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004-2008)

Pediatric Blood and Cancer

Volumn 60, Issue 7, 2013, Pages 1178-1183

  Neufeld, Ellis J ^a   Saxena, Kapil ^a   Kessler, Craig M ^b   Cooper, David L ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c NOVO NORDISK INC   (United States)

Author keywords

Hemophilia; Inhibitors; Registry; RFVIIa; Safety

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHILD; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; FUNCTIONAL STATUS; HEMOPHILIA A; HEPATITIS B; HEPATITIS C; HOSPITALIZED CHILD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COAGULANTS; FACTOR VIIA; FEMALE; HEMOPHILIA A; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REGISTRIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84878228164     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24472     Document Type: Article

References (20)

1. Bech RM. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996;26:135-138.
2. Lusher JM. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996;26:124-130.
3. Lusher J, Ingerslev J, Roberts H, et al. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998;9:119-128.
4. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998;4:790-798.
5. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-918.
6. Young G, Shafer FE, Rojas P, et al. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomized comparison. Haemophilia 2008;14:287-294.
7. Kenet G, Lubetsky A, Luboshitz J, et al. A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003;1:450-455.
8. Santagostino E, Mancuso ME, Rocino A, et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006;4:367-371.
9. Kavakli K, Makris M, Zulfikar B, et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006;95:600-605.
10. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80:773-778.
11. Villar A, Aronis S, Morfini M, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004;10:352-359.
12. Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 2008;65:3-11.
13. Valentino LA, Walsh CE, Reding MT, et al. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: Analysis of the Dosing Observational Study in Haemophilia (DOSE). Haemophilia 2012;18:554-560.
14. Young G, Shapiro AD, Walsh CE, et al. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: Home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia 2012;18:392-399.
15. Gruppo RA, Kessler CM, Neufeld EJ, et al. Assessment of individual dose utilization versus physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in pediatric and adult patients with congenital hemophilia and alloantibody inhibitors (CHwI): The Dosing Observational Study in Hemophilia (DOSE). Haemophilia (in press).
16. Young G, Cooper DL, Gut RZ. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: The experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008). Haemophilia 2012;18:990-996.
17. Santagostino E, Chambost H, Kavakli K, et al. Real world outcomes associated with the treatment of acute bleeds with rFVIIA in haemophilia patients with inhibitors: Results from the international one registry. International Society on Thrombosis and Haemostasis 2011 Annual Meeting (P-WE-520). J Thromb Haemostasis 2011;9:1-970.
18. Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004;2:899-909.
19. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008;14:898-902.
20. Ingerslev J, Sorensen B. Parallel use of by-passing agents in haemophilia with inhibitors: A critical review. Br J Haematol 2011;155:256-262.